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Essay
“What is the purpose of publications?…[The] 
purpose of data is to support, directly or indirectly, 
the marketing of our product.” [1] 
From Ghost Writing to Ghost 
Management
There are many reports of medical 
journal articles being researched 
and written by or on behalf of 
pharmaceutical companies, and 
then published under the name of 
academics who had played little role 
earlier in the research and writing 
process [2–14]. In extreme cases, drug 
companies pay for trials by contract 
research organizations (CROs), analyze 
the data in-house, have professionals 
write manuscripts, ask academics to 
serve as authors of those manuscripts, 
and pay communication companies to 
shepherd them through publication 
in the best journals. The resulting 
articles affect the conclusions found in 
the medical literature, and are used in 
promoting drugs to doctors.
For example, as reported in The New 
York Times [4], an Annals of Internal 
Medicine article on Merck’s “Advantage” 
trial of Vioxx omitted some trial 
participants’ deaths. Distancing himself 
from the Annals article, ﬁ  rst author 
Jeffrey Lisse said in an interview that 
“Merck designed the trial, paid for the 
trial, ran the trial…Merck came to me 
after the study was completed and said, 
‘We want your help to work on the 
paper.’ The initial paper was written at 
Merck, and then it was sent to me for 
editing” [4]. 
Such incidents have provoked many 
commentaries about ghost writing in 
the medical press. This article enlarges 
the focus from ghost writing to the 
more general ghost management of 
medical research and publishing: when 
pharmaceutical companies and their 
agents control or shape multiple steps 
in the research, analysis, writing, and 
publication of articles. Such articles are 
“ghostly” because signs of their actual 
production are largely invisible—
academic authors whose names appear 
at the tops of ghost-managed articles 
give corporate research a veneer of 
independence and credibility. They are 
“managed” because those companies 
shape the eventual message conveyed 
by the article or by a suite of articles. 
As discussed below, a substantial 
percentage of medical journal articles 
(in addition to meeting presentations 
and other forms of publication, which 
are not the focus here) are ghost 
managed, allowing the pharmaceutical 
industry considerable inﬂ  uence on 
medical research, and making that 
research a vehicle for marketing.
Ghost writing and honorary 
authorship are not in and of themselves 
scientiﬁ  c problems, though they 
become so when they shape science 
to meet particular interests [1]. 
Some honorary authors are senior 
professors and chairs of departments, 
who are added to articles because of 
local academic politics rather than 
at the request of drug companies 
[15,16]. Some busy independent 
research units hire writers to improve 
manuscripts; Max Lagnado has argued 
that professional medical writers can 
“beneﬁ  t the scientiﬁ  c community when 
used in a responsible manner” [15]. In 
any case, the writing of a manuscript 
may not be the key point at which 
behind-the-scenes inﬂ  uence is exerted: 
study design, statistical analysis, or the 
choice of placement of manuscripts 
may be equally important.
It has been repeatedly and ﬁ  rmly 
established that pharmaceutical 
company funding strongly biases 
published results in favor of the 
company’s products [17–19]. Ghost 
management ampliﬁ  es that bias, because 
when one set of commercial interests 
exerts inﬂ  uence at multiple stages of 
research, writing, and publication, it will 
shape the resulting article. In turn, bias 
affects medical opinion and practice, 
and ultimately, patients.
How Common Is Ghost 
Management?
Because ghost management is hidden, 
we cannot tell how common it is from 
published exposés. Current practices in 
the medical sciences legitimately allow 
people to serve as authors on the basis 
of narrow contributions. Therefore 
many near-honorary authors ﬁ  nd little 
reason to feel uncomfortable with 
their roles. Fully honorary authors may 
not see enough of the process of the 
production of their articles to know 
that they are ghost managed. Finally, 
it is not in the interests of writers, 
authors, or sponsors and their agents 
to reveal ghost management processes; 
hence a number of the published 
accounts of ghost management have 
stemmed from legal proceedings 
and investigative journalism. So how 
common is ghost management?
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Much of the information on ghost 
writing does not help to answer this 
question. Surveys to quantify rates of 
ghost writing do not address the ghost 
management phenomenon, because 
management may not involve writing, 
and writing may not be managed 
[20,21]. However, information about 
ghost authors, people who should 
be receiving author credit, strongly 
suggests that ghost management is 
common. A study comparing protocols 
and corresponding publications for 
industry-initiated trials approved by 
the Scientiﬁ  c-Ethical Committees 
for Copenhagen and Frederiksberg 
in 1994–1995 found evidence of 
ghost authorship in 75% of these 
publications (95% conﬁ  dence intervals, 
60%–87%) [22]. Company statisticians 
were common unacknowledged 
contributors, but so were the creators 
of trial designs and protocols, and the 
writers of manuscripts. The study also 
found that most (172 of 274) trials for 
which protocols had been submitted 
were never begun, completed, or 
published.
A Benchmark Study
The most solid information available 
on ghost management comes from the 
work of David Healy and Dinah Cattell. 
A lawsuit in which Healy was involved 
allowed access to a document listing 
85 manuscripts on sertraline that were 
being coordinated for Pﬁ  zer by the 
medical education and communication 
company (MECC) Current Medical 
Directions (CMD) [9,23]. The 
document lists other agencies as the 
vendors of some of the documents, 
and some authors “TBD” (to be 
determined), so it is almost certain that 
a number of these 85 manuscripts were 
written by professional writers acting 
for Pﬁ  zer, possibly via CMD. 
More importantly, all of the 
manuscripts were being managed 
very carefully, as CMD was aware of 
submission dates, journals’ requests 
for revisions, target dates for those 
revisions, and projected publication 
dates. Authors were not acting 
independently. The document is 
peppered with comments such as “First 
draft with author for review,” and 
“Manuscript submitted to American 
Journal of Psychiatry 7/98. Conﬁ  dence 
intervals requested by journal. Revised 
manuscript resubmitted 9/98” [24]. 
Most manuscripts were published in 
prestigious medical journals between 
1998 and 2000, with academic 
researchers listed as their authors. 
The resulting articles are Pﬁ  zer’s 
early contribution on the literature 
on sertraline, but bear few marks of 
Pﬁ  zer’s inﬂ  uence, let alone disclosure 
of Pﬁ  zer’s contributions to multiple 
stages of their research, writing, and 
submission.
These 85 manuscripts became 
a signiﬁ  cant portion of all of the 
articles published on sertraline. A 
general Medline search of 1998 to 
2000 (performed December 2006) 
found 479 results with the keyword 
“sertraline,” and 211 with “sertraline” 
in the title. This suggests that between 
18% and 40% of articles on sertraline 
in this key period were managed by 
Pﬁ  zer through this one MECC, large 
enough percentages to have substantial 
effects on the overall shape of the 
medical literature on this drug. 
Healy and Cattell claim that the 
CMD articles are uniformly positive 
about sertraline, and they note under-
reporting of side effects in these 
articles. Compared to other articles on 
sertraline (i.e., those not coordinated 
by CMD), the CMD articles were 
published in more prominent journals, 
had nearly twice as many authors 
per article, had authors who were on 
average twice as proliﬁ  c, and garnered 
nearly three times as many citations 
(20.2 versus 7.7 in Healy and Cattell’s 
analysis) [23]. Apparently, CMD was 
effective at helping publish these 
articles in a visible way.
While we cannot know all of the 
ways in which the CMD document 
represents other publication efforts, 
there is strong evidence that ghost 
management of medical research is 
common and is part of campaigns by 
pharmaceutical companies to publish 
favorable results and key marketing 
messages.
MECCs and Ghost Management: A 
Supply-Side Analysis
A survey in 2001 identiﬁ  ed 182 MECCs 
in the United States, up from 153 
in 1998 [25]. A number specialize 
in producing, placing, and tracking 
journal articles, known in the trade as 
“publication planning” or “strategic 
communication planning.” While these 
ﬁ  rms hide details of their work—from 
potential critics and competitors—they 
also energetically promote themselves 
and their services. Many have ﬂ  ashy 
Web sites highlighting their ability to 
prepare meeting presentations and 
publish articles. 
In preparing this article, I spent six 
hours searching web pages for MECCs 
offering publication planning or 
similar or overlapping services to the 
pharmaceutical industry, and found 23 
(list available from the author). This 
is not an estimate of the number of 
such ﬁ  rms, but indicates how common 
they are. There may be many more 
ﬁ  rms providing publication planning, 
including some not uncovered in this 
search, and some not advertising these 
services on the Internet. For example, 
CMD was not among the 23 found, as 
its current Web site lists only medical 
education and meeting services as core 
capabilities. Pharmaceutical companies 
also do publication planning in-house, 
though one industry source estimates 
that in-house planning makes up 
only 20% of this business [26]. On 
the other side, it is possible that some 
of the identiﬁ  ed ﬁ  rms misrepresent 
themselves, and perform only minimal 
publication planning.
Pharmaceutical companies control 
an immense quantity of data. The 
industry provides twice as much 
funding for clinical trials and related 
research as do not-for-proﬁ  t agencies 
[27]. Of industry funding, 70% goes 
to CROs that neither make ownership 
claims on data nor expect to publish 
the data themselves: CROs perform 
research to order [28]. By its nature 
CRO research tends to be ghostly. 
The 30% of industry funding that goes 
to academic researchers often also 
comes with strings attached that can 
allow sponsors to prepare drafts, edit 
drafts, delay publication, prevent full 
access to data, and so on—in short, 
creating conditions that allow for ghost 
management [29–31].
In a primer on publication planning, 
the director of one MECC deﬁ  nes the 
activity as: “gaining product adoption 
and usage through the systematic, 
planned dissemination of key messages 
and data to appropriate target 
audiences at the optimum time using 
the most effective communication 
channels” [32]. These channels 
are such things as: “publications, 
journal reviews, symposia, workshops, 
advisory boards, abstracts, educational 
materials/PR.” Inﬂ  uencing scientiﬁ  c 
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is the clearly stated goal here. The 
author of this article therefore makes 
scientiﬁ  c and commercial goals equal 
stakeholders in communication: in a 
chart he juxtaposes “Where shall we 
publish this study?” with “Who are our 
customers?” and “What can we claim 
from the results?” with “What are our 
customer needs?”
Complete Healthcare 
Communications (CHC) claims on its 
banner that it “has honed the systems 
and skills needed to develop the 
intellectual heart of pharmaceutical 
marketing—the publication plan. The 
result for your product? A continuum 
of awareness, interest, and prescriber 
conﬁ  dence” [33]. CHC will manage 
article submissions to meetings, and 
as samples of its service it provides 
hypothetical lists of abstracts and 
presentations, with their status, dates of 
presentation, etc. On its Web site is a 
list of ten hypothetical trials and at least 
24 articles that can be written from 
them, which will lead to a completed 
bibliography of publications [34].
CHC includes among its clients 
Pﬁ  zer, Sanoﬁ  -Aventis, Ortho Biotech, 
Wyeth, Schering-Plough, Shire, 
AstraZeneca, and other pharmaceutical 
companies. It provides testimonials 
from sponsors and authors. A Johns 
Hopkins author writes “Very nice 
outline! You guys are quite organized!! 
I think it’s superb. Very fair and 
balanced. I’m not used to working with 
such excellent writers!” CHC claims to 
have written and submitted over 500 
manuscripts, with an acceptance rate of 
80%. CHC is able to achieve such a rate 
with resources far beyond the reach of 
most researchers: not only are all of its 
studies fully supported by the largest 
of pharmaceutical companies, but it 
boasts a team of 40 medical writers, 
editors, and librarians.
Other agencies offer very similar 
services. As described in an article by 
three of its managers, the Medical 
Knowledge Group starts publication 
planning with a phase of exploring 
“key messages” and “author/journal 
options” before designing any 
publications to incorporate those 
messages [35]. It then tracks those and 
competitors’ messages using its own 
information management tool. (Like 
CMD, the Medical Knowledge Group 
was not included when I conducted 
my web search, underscoring the 
limitations of that search.) Another 
MECC, Envision Pharma, says that “data 
generated from clinical trials programs 
are the most powerful marketing 
tools available to a pharmaceutical 
company.” Envision will work from 
early on in the process to ensure 
“consistent message dissemination,” will 
plan and track the “data dissemination 
plan,” and will produce “scientiﬁ  cally 
accurate, commercially focused 
abstracts, posters, and primary and 
secondary publications” [36].
In addition to the publication 
planners, a much higher number 
of medical writing companies and 
individual writers create articles 
and presentations without engaging 
in broader publication planning; 
these may be adjuncts to publication 
planners. To provide an indication of 
the scale, the American Medical Writers 
Association boasts a membership of 
more than 5,000 [37]; judging from the 
organization’s ofﬁ  cers and the content 
of its conferences, it appears to be 
dominated by MECCs [38,39].
Several of the publication 
planning ﬁ  rms identiﬁ  ed are owned 
by major publishing houses. For 
example, Excerpta Medica is “an 
Elsevier business” and writes that its 
“relationship with Elsevier allows…
access to editors and editorial boards 
who provide professional advice and 
deep opinion leader networks” [40]. 
Wolters Kluwer Health draws attention 
to its publisher Lippincott Williams & 
Wilkins, with “nearly 275 periodicals 
and 1,500 books in more than 100 
disciplines,” and to Ovid and its 
other medical information providers, 
emphasizing the links it can make 
between its different arms [41]. Vertical 
integration is attractive in the industry 
as a whole: at least three of the world’s 
largest advertising agencies own not 
only MECCs, but also CROs [13].
Ghost management of medical 
journal publications is clearly a 
substantial business, employing 
thousands of marketers, writers, 
and managers. It is large enough 
that the industry has established the 
International Publication Planning 
Association. This organization, 
which appears to be dominated by 
pharmaceutical companies, organizes 
meetings, keeps a directory of experts, 
and gives awards to honor planners 
[42]. In addition, the International 
Society for Medical Publication 
Professionals also organizes meetings, 
has committees to develop policy, and 
posts job advertisements [43]. Both 
of these associations compete with 
for-proﬁ  t companies offering similar 
services, such as the Center for Business 
Intelligence, which held forums for 
Strategic Publication Planning in 2005 
and 2006 [44].
Discussion
Merck’s ghost management of the 
Advantage trial paper was described 
as “an unusual practice” when it 
was reported in The New York Times 
[4]. Given the amount of data that 
pharmaceutical companies control, 
the number of publication planning 
agencies that openly advertise on 
the Internet, the number of medical 
writers, the existence of two associations 
for publication planners, and meetings 
organized and reports written for 
them, we can conclude that ghost 
management is common. The CMD 
document obtained by Healy suggests 
that during key marketing periods 
as many as 40% of published articles 
focusing on speciﬁ  c drugs are ghost 
managed [24]. Even if the more typical 
ﬁ  gure is half that, ghost management 
exerts a huge force on the shape of 
scientiﬁ  c opinion on new drugs, and 
does so in the service of marketing.
Articles in medical journals have 
real effects upon physician prescribing 
behavior, which is why pharmaceutical 
companies invest so much in their 
publication. Journal articles are heavily 
used in detailing, to validate claims 
and rebut worries. Even independent 
of detailers, responsible physicians 
and medical researchers search the 
literature to gather evidence about 
the best treatments. Published 
scientiﬁ  c articles are the sources of 
medical information with the highest 
authority. Systematic reviews and 
meta-analyses almost all start with the 
published literature—so even fully 
independent reviews are inﬂ  uenced by 
ghostly activities. Therefore, the ghost 
management of journal articles is a 
step in the intervention into medical 
practice.
There are no straightforward 
solutions, short of large changes to the 
nature of medical publishing and/or 
research, changes that would effectively 
sequester pharmaceutical company 
funding from research and publishing 
[45] or from marketing [46]. Until 
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can hope for more awareness of and 
responsiveness to the issue.
Peer review has not been proven to 
be an effective tool for quality control, 
so we cannot rely on journals’ peer 
review systems to guard against biases 
created by ghost managing [47–49]. 
Indeed, MECCs are effective at creating 
publishable articles and getting them 
published in peer-reviewed journals. 
Nor are current disclosure measures 
effective. Major journals have put in 
place strong disclosure procedures, 
but while these might disallow 
extreme forms of ghost management, 
many forms of it do not run afoul 
of any rules other than failure to 
acknowledge some contributors and 
facilitators. With awareness of the 
issue, however, perhaps journal editors 
can recognize signs of behind-the-
scenes work. They can refuse to deal 
directly with publication planners, 
and they can ask authors repeatedly 
about under-recognized and over-
recognized contributors, facilitators, 
and inﬂ  uences; systematic adoption 
of a strong “ﬁ  lm credit model” of 
authorship, in which authors rigidly 
and closely specify their roles, might aid 
in those efforts [50]. Such efforts would 
have to go hand-in-hand with penalties 
for misconduct [12]. Although not 
discussed here, MECCs ghost manage 
other forms of publication including 
academic meeting presentations, and 
thus program committees of these 
meetings face similar issues.
Universities and academic health 
centers should prohibit contracts that 
allow sponsors to draft, edit, or suppress 
articles, or that allow sponsors to keep 
data from authors; they should even 
prohibit sponsors from facilitating 
publication. Universities should 
also take disciplinary action against 
investigators who serve as authors on 
ghost-managed articles. Meanwhile, 
investigators need to be aware of the 
mechanisms of ghost management of 
work that goes under their names, and 
to refuse to participate. Perhaps they 
need to be more modest about how 
many articles they can publish, and 
more realistic about the amount of 
effort, legwork, and/or creativity it takes 
to publish an article. In a presentation 
on its Web site, the MECC Envision 
mentions the “author dilemma: Who 
are they? Why are they authors? What is 
their role?” [51] All authors should ask 
the same questions of themselves.  
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